Article Data

  • Views 293
  • Dowloads 113

Original Research

Open Access

Immunohistochemical evaluation of a new epithelial antigen, BER-EP4 in ovarian cancer: a propos of 62 cases

  • G. Capobianco1
  • V. Marras2
  • G. Battista Meloni3
  • S. Dessole1
  • N. Ashqar1
  • C. Cherchi1
  • F. Dessole1
  • P.L. CHERCHI1,*,

1Gynecologic and Obstetric Clinic, Sassari, Italy

2Institute of Pathology, Sassari, Italy

3Institute of Radiology, University of Sassari, Sassari, Italy

DOI: 10.12892/ejgo20120190 Vol.33,Issue 1,January 2012 pp.90-92

Published: 10 January 2012

*Corresponding Author(s): P.L. CHERCHI E-mail:


Objective: To assess the immunohistochemical expression of BerEP4, a new epithelial antigen in ovarian cancer. Methods: We studied 62 cases of ovarian cancer in which BerEP4, CEA and CA-125 were investigated by an immunohistochemical method. We evaluated the correlations among immunohistochemical positivity and the grading, histotype and stage of disease. Results: BerEP4 was positive in 45 out of 62 cases (72.58%), CA-125 in 36 out of 62 cases (58.06%) and CEA in ten out of 62 cases (16.13%). BerEP4 was present both in serous and in mucinous tumors (80.96% vs 80.77%). CA-125 was mainly expressed in serous vs mucinous tumors (66.67% vs 57.69%). CEA was more prevalent in mucinous vs serous tumors. Ber-EP4 was mainly expressed in G1 (75%) and G2 (77.27%). CA-125 was more present in G1 and G3 (both 62.50%) than G2 (50%), whereas CEA showed positivity in G1: 12.50%, G2: 22.73% and G3: 12.50%. There were no differences among the three antigens studied with regard to clinical stage. Conclusions: In our study Ber-EP4 was positive in 45 out of 62 cases (72.58%) of primary epithelial ovarian cancers. The presence of this antigen seemed to be related to the histotype and grading but not to clinical stage.


Epithelial antigen; BerEP4; Ovarian cancer

Cite and Share

G. Capobianco,V. Marras,G. Battista Meloni,S. Dessole,N. Ashqar,C. Cherchi,F. Dessole,P.L. CHERCHI. Immunohistochemical evaluation of a new epithelial antigen, BER-EP4 in ovarian cancer: a propos of 62 cases. European Journal of Gynaecological Oncology. 2012. 33(1);90-92.


[1] Taylor K.J., Schwartz P.E.: “Cancer screening in a high risk population: a clinical trial”. Ultrasound Med. Biol., 2001, 27, 461.

[2] Woolas R.P., Oram D.H., Jeyarajah A.R., Bast R.C., Jacobs I.J.: “Ovarian cancer identified through screening with serum markers but not by pelvic imaging”. Int. J. Gynecol. Cancer, 1999, 9, 497.

[3] Partridge E.E., Barnes M.N.: “Epithelial ovarian cancer: prevention, diagnosis and treatment”. C.A. Cancer J. Clin., 1999, 49, 297.

[4] Van Dalen A., Favier J., Baumgartner L., Hasholzner U., De Bruijn H., Dobbler D. et al.: “Serum levels of CA 125 and TPS during treatment of ovarian cancer”. Anticancer Res., 2000, 20, 5107.

[5] Zurawski V.R., Knapp R.C., Einhorn N., Kenemans P., Mortel R., Ohmi K. et al.: “An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma”. Gynecol. Oncol., 1988, 30, 7.

[6] Tuxen M.K., Soletormos G., Rustin G.J., Nelstrop A.E., Dombernowsky P.: “Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer”. Scand. J. Clin. Lab. Invest., 2000, 60, 713.

[7] Nyvang G.B., Mogensen O., Bichel P., Jakobsen A.: “Combined prognostic importance of CA 125, histopathologic grade and DNA-index in advanced ovarian cancer”. Eur. J. Gynaecol. Oncol., 2000, 21, 569.

[8] Runnebaum I.B., Stickeler E.: “Epidemiological and molecular aspects of ovarian cancer risk”. J. Cancer Res. Clin. Oncol., 2001, 127, 73.

[9] Morrow C.P., Curtin J.P. (eds.): “Surgery for ovarian neoplasia”. In: Gynecologic Cancer Surgery. New York, Churchill Livingstone, 1996, 627.

[10] Elit L.: “Familial ovarian cancer”. Can. Fam. Physician, 2001, 47, 778.

[11] Werness B.A., Eltabbakh G.H.: “Familial ovarian cancer and early ovarian cancer: biologic, pathologic and clinical features”. Int. J. Gynecol. Pathol., 2001, 20, 48.

[12] Gitsch G., Tabery U., Feigl W., Breitenecker G.: “The differential diagnosis of primary peritoneal papillary tumors”. Arch. Gynecol. Obstet., 1992, 251, 139.

[13] Baker P.M., Oliva E., Young R.H., Talerman A., Scully R.E.: “Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases”. Am. J. Surg. Pathol., 2001, 25, 557.

[14] Latza U., Niedobitek G., Schwarting R., Nekarda H., Stein H.: “Ber-EP4. New monoclonal antibody which distinguishes epithelia from mesothelia“. J. Clin. Pathol., 1990, 43, 213.

[15] Cherchi P.L., Bosincu L., Dessole S., Ruiu G.A., Cossu Rocca P., Capobianco G. et al: “Immunohistochemical expression of BerEP4, a new epithelial antigen, in endometrial carcinoma: correlation with clinical parameters”. Eur. J. Gynaecol. Oncol., 1999, 20, 393.

[16] Manjunath A.P., Pratapkumar, Sujatha K., Vani R.: “Comparison of three risk of malignancy indices in evaluation of pelvic masses”. Gynecol. Oncol., 2001, 81, 225.

[17] Davidson B., Risberg B., Kristensen G., Kvalheim G., Emilsen E., Bjamer A. et al.: “Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers”. Virchows Arch., 1999, 435, 43.

[18] Comin C.E., Saieva C., Messerini L: “h-Caldesomn, Calretinin, Estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary”. Am. J. Pathol., 2007, 31, 1139.

[19] Okamoto S., Ito K., Sasano H., Moriya T., Niikura H., Terada Y.: “Ber-EP4 and anti -calretinin antibodies: a useful combination for differentiating diagnosis of various histological types of ovarian cancer cells and mesothelial cells”. Tohoku J. Exp. Med., 2005, 206, 31.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time